Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 141 to 150 of 220 total matches.

In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
toxicity occurs or up to 3 years. Dostarlimab should be given before chemotherapy if they are both given ...
The immune checkpoint inhibitor dostarlimab-gxly (Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138   doi:10.58347/tml.2023.1683f |  Show IntroductionHide Introduction

In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
, AND COST — Cyclophosphamide and fludarabine lymphodepleting chemotherapy should be administered before ...
Obecabtagene autoleucel (Aucatzyl – Autolus), a CD19-directed genetically modified autologous T cell immunotherapy, has been approved by the FDA for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. The CAR T-cell immunotherapy products tisagenlecleucel (Kymriah) and brexucabtagene auto-leucel (Tecartus) were approved earlier for the same indication.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):e208   doi:10.58347/tml.2024.1718f |  Show IntroductionHide Introduction

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
has been more effective than chemotherapy for first-line treatment of ALK-positive metastatic NSCLC.1 About 60 ...
The FDA has approved brigatinib (Alunbrig – Takeda), an oral tyrosine kinase inhibitor, for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma. Brigatinib is the third tyrosine kinase inhibitor to be approved for this indication; ceritinib (Zykadia) and alectinib (Alecensa) were approved earlier, and subsequently were...
Med Lett Drugs Ther. 2018 Apr 23;60(1545):e72-3 |  Show IntroductionHide Introduction

Goserelin - Another LH-RH Analog for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990  (Issue 830)
COPYRIGHT LAWS flutamide Eulexin of goserelin Cost goserelin for prostate cancer Cancer chemotherapy ...
The US Food and Drug Administration recently approved the marketing of goserelin acetate (Zoladex - ICI Pharma), an implant for palliative treatment of advanced prostate cancer. Goserelin acetate is a synthetic decapeptide luteinizing hormone-releasing hormone (LH-RH) analog similar to leuprolide (Lupron; Lupron Depot) (Medical Letter, 27:71, 1985).
Med Lett Drugs Ther. 1990 Nov 2;32(830):102 |  Show IntroductionHide Introduction

Idarubicin

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991  (Issue 852)
Cerubidine idarubicin for AML Cancer chemotherapy Antacids Adriamycin cytarabine daunorubicin doxorubicin ...
Idarubicin hydrochloride (Idamycin - Adria), an anthracycline structurally related to daunorubicin (Cerubidine, and others) and doxorubicin (Adriamycin, and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
Med Lett Drugs Ther. 1991 Sep 6;33(852):84-5 |  Show IntroductionHide Introduction

In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
chemotherapy (cyclophosphamide and fludarabine). CLINICAL STUDIES — FDA approval of the CD19-directed CAR ...
Brexucabtagene autoleucel (Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. Tecartus is an individualized cellular product prepared from the patients own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell immunotherapy tisagenlecleucel (Kymriah) was approved in 2017 for treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6   doi:10.58347/tml.2023.1678f |  Show IntroductionHide Introduction

Flutamide For Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989  (Issue 797)
IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS Cancer chemotherapy flutamide Cost of flutamide ...
Flutamide (Eulexin - Schering), an oral antiandrogen, is now available in the USA for treatment of metastatic prostate cancer. Flutamide is recommended by the manufacturer only for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron - Medical Letter, 27:71, 1985).
Med Lett Drugs Ther. 1989 Jul 28;31(797):72 |  Show IntroductionHide Introduction

Topotecan Hydrochloride for Metastatic Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996  (Issue 986)
cisplatin carboplatin topotecan for ovarian Cancer chemotherapy Cytoxan Hycamtin Topotecan for metastatic ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).
Med Lett Drugs Ther. 1996 Oct 25;38(986):96-7 |  Show IntroductionHide Introduction

Gliadel Wafers for Treatment of Brain Tumors

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 1998  (Issue 1035)
COPYRIGHT LAWS BiCNU Cancer chemotherapy carmustine Carmustine wafer for brain tumor Gliadel wafers ...
A biodegradable polymer 'wafer' (Gliadel - Rh ne-Poulenc Rorer) impregnated with the alkylating agent carmustine (BCNU; Bicnu) has been marketed in the USA for local treatment of recurrent glioblastoma multiforme that requires re-operation. The dime-sized polyanhydride wafers are implanted into the surgical cavity left behind after resection. Release of the alkylating agent directly into the area of the tumor bypasses the blood-brain barrier (H Brem and R Langer, Sci Med, 3:1, 1996).
Med Lett Drugs Ther. 1998 Sep 11;40(1035):92 |  Show IntroductionHide Introduction

Ceritinib (Zykadia) for Non-Small Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
patients and trials comparing it to chemotherapy in treatment-naive and previouslytreated patients ...
Ceritinib (Zykadia – Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). It is the second tyrosine kinase inhibitor to be approved for ALK-positive metastatic NSCLC; crizotinib was the first. Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma.
Med Lett Drugs Ther. 2014 Jul 21;56(1447):62-3 |  Show IntroductionHide Introduction